Core Viewpoint - The company, 加科思-B, has entered into a licensing and collaboration agreement with AstraZeneca AB to develop and commercialize the pan-KRAS inhibitor JAB-23E73, which includes significant financial terms and joint development responsibilities in specific regions [1]. Group 1: Agreement Details - The agreement grants AstraZeneca an exclusive license to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]. - In mainland China, the product will be jointly developed and commercially collaborated under a governance framework established in the agreement [1]. Group 2: Financial Terms - 北京加科思 is entitled to receive an upfront payment of $100 million from AstraZeneca [1]. - The company is also eligible for additional milestone payments that could total up to $1.915 billion upon achieving various development, regulatory, and commercial milestones [1]. - Upon successful commercialization of the licensed product, 北京加科思 will receive tiered royalties based on the net sales of the product [1].
加科思-B附属与阿斯利康订立许可与合作协议 以开发及商业化泛KRAS抑制剂JAB-23E73